Compliance with these regulations is crucial for gaining approval to market a drug.10 Toll-like receptor 4 (TLR4) is a member of the pattern recognition receptor family, which is important for the human defence system and has a very sensitive and selective response to invasive pathogens.11 Numerous medications that target TLR4 are currently undergoing clinical trials, and the two FDA-approved medications, monophosphoryl lipid A (MPLA) for the treatment of bladder and cervical cancer and Bacillus Calmette–Guerin, a vaccine against tuberculosis, are readily available.12 Here, TLR4 is linked to cervical carcinoma.